BioMerieux SA (OTCMKTS:BMXMF) – Equities researchers at Piper Jaffray Companies dropped their FY2019 earnings estimates for shares of BioMerieux in a note issued to investors on Tuesday, October 22nd. Piper Jaffray Companies analyst W. Quirk now anticipates that the company will post earnings per share of $2.72 for the year, down from their previous estimate of $2.86.
Separately, Zacks Investment Research cut BioMerieux from a “buy” rating to a “hold” rating in a research note on Wednesday.
BioMerieux Company Profile
bioMérieux SA provides vitro diagnostic solutions systems for private and hospital laboratories, primarily for the diagnosis of infectious diseases. The company offers microbiology technology that involves culturing biological samples; and immunoassays technology based on antigen-antibody reaction, detects and measures infectious agents, such as bacteria, viruses, and parasites, as well as measures the specific biomarkers of various pathologies, such as metabolic, hormonal, infectious, etc.
Featured Article: What is a price target?
Receive News & Ratings for BioMerieux Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMerieux and related companies with MarketBeat.com's FREE daily email newsletter.